Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00401401 · ClinicalTrials.gov registry record · Phase 1
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
A Phase 1 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00401401 is a Phase 1 study that was terminated before completion, run by Genmab. The registered enrollment target is 30 participants.
The verdict
NCT00401401, a Phase 1 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
Interventions
- DRUG cisplatin
- PROCEDURE Radiotherapy
- DRUG zalutumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00401401
The ClinicalTrials.gov registry entry for NCT00401401 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00401401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00401401 about?
NCT00401401 is a clinical study titled "Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer". The purpose of this study is to investigate the safety of zalutumumab in combination with chemotherapy and radiotherapy as treatment of patients with head and neck cancer
What is the current status of trial NCT00401401?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2006-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00401401?
The interventions under investigation include: cisplatin (DRUG), Radiotherapy (PROCEDURE), zalutumumab (DRUG).
Who is sponsoring clinical trial NCT00401401?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.